Evidence map›Paper›PMID 33323099›Full record

ArticleBMC bioinformatics2020

DRACP: a novel method for identification of anticancer peptides.

Tianyi Zhao, Yang Hu, Tianyi Zang

Abstract read
In one paragraph

Article in BMC bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Anti-Cancer Peptides: Status and Future Prospects.Molecules (Basel, Switzerland) · 2023
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tianyi ZhaoDepartment of Computer Science and Technology, School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Yang HuDepartment of Computer Science and Technology, School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Tianyi ZangDepartment of Computer Science and Technology, School of Life Science and Technology, Harbin Institute of Technology, Harbin, China. tianyi.zang@hit.edu.cn.ORCID http://orcid.org/0000-0003-0195-8731

Funding

National Basic Research Program of China (973 Program) (CN) 2016YFC0901605National Major Science and Technology Projects of China 2016YFC1202302
6 · The paper itself

Abstract

backgroundMillions of people are suffering from cancers, but accurate early diagnosis and effective treatment are still tough for all doctors. Common ways against cancer include surgical operation, radiotherapy and chemotherapy. However, they are all very harmful for patients. Recently, the anticancer peptides (ACPs) have been discovered to be a potential way to treat cancer. Since ACPs are natural biologics, they are safer than other methods. However, the experimental technology is an expensive way to find ACPs so we purpose a new machine learning method to identify the ACPs.

resultsFirstly, we extracted the feature of ACPs in two aspects: sequence and chemical characteristics of amino acids. For sequence, average 20 amino acids composition was extracted. For chemical characteristics, we classified amino acids into six groups based on the patterns of hydrophobic and hydrophilic residues. Then, deep belief network has been used to encode the features of ACPs. Finally, we purposed Random Relevance Vector Machines to identify the true ACPs. We call this method 'DRACP' and tested the performance of it on two independent datasets. Its AUC and AUPR are higher than 0.9 in both datasets.

conclusionWe developed a novel method named 'DRACP' and compared it with some traditional methods. The cross-validation results showed its effectiveness in identifying ACPs.

Indexed as

Antineoplastic AgentsComputational BiologyHumansMachine LearningNeoplasmsPeptidesROC CurveSupport Vector MachineAntineoplastic AgentsPeptidesAnticancer peptidesCancerDeep belief networkRandom forestRelevance vector machine

Identifiers

PMID33323099
PMCPMC7739480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.